- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Danielle Kirkman: Recent Findings on Exercise and Hypertension in Patients With Kidney Disease
Recent findings have shown that aerobic exercise improves microvascular function and coronary artery function in patients with kidney disease, but further research is needed on the relationship between exercise and kidney function, said Danielle Kirkman, PhD, assistant professor at Virginia Commonwealth University.
Recent findings have shown that aerobic exercise improves microvascular function and coronary artery function in patients with kidney disease, but further research is needed on the relationship between exercise and kidney function, said Danielle Kirkman, PhD, assistant professor at Virginia Commonwealth University.
Transcript
What are some recent findings about the role of exercise in hypertension and kidney disease?
Some recent findings from our group at University of Delaware where I studied my postdoc, we recently found that aerobic exercise in nondialysis kidney disease patients significantly improved microvascular function and coronary artery function, so these are both implicated in the development of hypertension, so certainly this could be playing a role in lowering blood pressure. Previous studies before ours have shown that specifically in the non—kidney disease population, aerobic exercise reduces blood pressure by about 4 to 5 mm Hg. Certainly there’s a lot more research to be done in this field; I think we need some larger multicenter trials looking at the effects of exercise in lowering blood pressure.
With regards to kidney function, I think this is an area that’s still pretty underinvestigated, and it’s really a hot topic for those involved with exercise and chronic kidney disease. We are still trying to figure out whether exercise reduces the progression of kidney disease, whether it improves kidney function and improves perfusion to the kidney.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More
